Resumen
Lysophosphatidic acid (LPA) is a synaptic phospholipid, which regulates cortical excitation/inhibition (E/I) balance and controls sensory information processing in mice and man. Altered synaptic LPA signaling was shown to be associated with psychiatric disorders. Here, we show that the LPA-synthesizing enzyme autotaxin (ATX) is expressed in the astrocytic compartment of excitatory synapses and modulates glutamatergic transmission. In astrocytes, ATX is sorted toward fine astrocytic processes and transported to excitatory but not inhibitory synapses. This ATX sorting, as well as the enzymatic activity of astrocyte-derived ATX are dynamically regulated by neuronal activity via astrocytic glutamate receptors. Pharmacological and genetic ATX inhibition both rescued schizophrenia-related hyperexcitability syndromes caused by altered bioactive lipid signaling in two genetic mouse models for psychiatric disorders. Interestingly, ATX inhibition did not affect naive animals. However, as our data suggested that pharmacological ATX inhibition is a general method to reverse cortical excitability, we applied ATX inhibition in a ketamine model of schizophrenia and rescued thereby the electrophysiological and behavioral schizophrenia-like phenotype. Our data show that astrocytic ATX is a novel modulator of glutamatergic transmission and that targeting ATX might be a versatile strategy for a novel drug therapy to treat cortical hyperexcitability in psychiatric disorders.
| Idioma original | English |
|---|---|
| Páginas (desde-hasta) | 1699-1710 |
| Número de páginas | 12 |
| Publicación | Molecular Psychiatry |
| Volumen | 23 |
| N.º | 8 |
| DOI | |
| Estado | Published - ago 1 2018 |
Nota bibliográfica
Publisher Copyright:© 2018, Macmillan Publishers Limited, part of Springer Nature.
Financiación
Acknowledgements We thank Cheryl Ernest for proofreading the manuscript, Silke Fregin for technical assistance and Nicolai Savaskan for providing the ATX-GFP construct. This work was supported by the Deutsche Forschungsgemeinschaft (SFB 1080 and 1193) to JV, RN, IT, JR, TS, KR and HJL, by the European Research Council (ERC-AG \u201CLiPsyD\u201D to RN) and by the Boehringer-Ingelheim Foundation to JV.
| Financiadores | Número del financiador |
|---|---|
| Boehringer-Ingelheim Foundation | |
| H2020 European Research Council | |
| U.S. Department of Veterans Affairs | I01CX001550 |
| U.S. Department of Veterans Affairs | |
| National Institute of General Medical Sciences DP2GM119177 Sophie Dumont National Institute of General Medical Sciences | P30GM127211, P20GM103527 |
| National Institute of General Medical Sciences DP2GM119177 Sophie Dumont National Institute of General Medical Sciences | |
| European Commission | 322907 |
| European Commission | |
| Deutsche Forschungsgemeinschaft | SFB 1080, 1193 |
| Deutsche Forschungsgemeinschaft |
ASJC Scopus subject areas
- Molecular Biology
- Cellular and Molecular Neuroscience
- Psychiatry and Mental health